

## Special Issue

# Chronic Lymphocytic Leukaemia (CLL)

### Message from the Guest Editor

Chronic lymphocytic leukemia is a rare cancer; however, as it has an incidence of almost 4 new cases in every 100,000 people/year, it is the most commonly occurring form of leukemia in western countries. In the last 15 years, our understanding of chronic lymphocytic leukemia has been revolutionized thanks to significant insights into the molecular biology of the disease and the interplay between neoplastic cells and the surrounding microenvironment. The identification of molecules pivotal to the survival of chronic lymphocytic leukemia cells has allowed us to develop targeted therapies (monoclonal antibodies, kinase inhibitors, BH3-mimetics, etc.) that have become the cornerstone of chronic lymphocytic leukemia treatment. Despite these advances, chronic lymphocytic leukemia remains an incurable disease and hypogammaglobulinemia, infections, and second primary malignancies still impinge upon patients' quality of life.

---

### Guest Editor

Prof. Dr. Livio Trentin

Hematology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy

---

### Deadline for manuscript submissions

closed (31 August 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/53380](https://mdpi.com/si/53380)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)